JP2019530713A - 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 - Google Patents

腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 Download PDF

Info

Publication number
JP2019530713A
JP2019530713A JP2019519669A JP2019519669A JP2019530713A JP 2019530713 A JP2019530713 A JP 2019530713A JP 2019519669 A JP2019519669 A JP 2019519669A JP 2019519669 A JP2019519669 A JP 2019519669A JP 2019530713 A JP2019530713 A JP 2019530713A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
administration
day
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019519669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530713A5 (enExample
Inventor
ラドコ コマース，
ラドコ コマース，
アルヴィン シー，
アルヴィン シー，
Original Assignee
レトロフィン， インコーポレイテッド
レトロフィン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レトロフィン， インコーポレイテッド, レトロフィン， インコーポレイテッド filed Critical レトロフィン， インコーポレイテッド
Publication of JP2019530713A publication Critical patent/JP2019530713A/ja
Publication of JP2019530713A5 publication Critical patent/JP2019530713A5/ja
Priority to JP2022113880A priority Critical patent/JP2022141802A/ja
Priority to JP2022113881A priority patent/JP2022137245A/ja
Priority to JP2024225044A priority patent/JP2025060754A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019519669A 2016-10-13 2017-10-13 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 Withdrawn JP2019530713A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022113880A JP2022141802A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2022113881A JP2022137245A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2024225044A JP2025060754A (ja) 2016-10-13 2024-12-20 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407860P 2016-10-13 2016-10-13
US62/407,860 2016-10-13
US201662423079P 2016-11-16 2016-11-16
US62/423,079 2016-11-16
PCT/US2017/056538 WO2018071784A1 (en) 2016-10-13 2017-10-13 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022113880A Division JP2022141802A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2022113881A Division JP2022137245A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Publications (2)

Publication Number Publication Date
JP2019530713A true JP2019530713A (ja) 2019-10-24
JP2019530713A5 JP2019530713A5 (enExample) 2020-11-19

Family

ID=60191503

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019519669A Withdrawn JP2019530713A (ja) 2016-10-13 2017-10-13 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2022113881A Pending JP2022137245A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2022113880A Pending JP2022141802A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2024225044A Pending JP2025060754A (ja) 2016-10-13 2024-12-20 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022113881A Pending JP2022137245A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2022113880A Pending JP2022141802A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2024225044A Pending JP2025060754A (ja) 2016-10-13 2024-12-20 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Country Status (11)

Country Link
US (5) US20190262317A1 (enExample)
EP (2) EP3525784B1 (enExample)
JP (4) JP2019530713A (enExample)
KR (4) KR102528435B1 (enExample)
CN (5) CN114788823A (enExample)
AU (3) AU2017341825B2 (enExample)
BR (1) BR112019007576A2 (enExample)
CA (1) CA3039819A1 (enExample)
ES (1) ES3067967T3 (enExample)
MA (1) MA46524A (enExample)
WO (1) WO2018071784A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507739A (ja) * 2019-12-17 2023-02-27 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンによるｉｇａ腎症を治療する方法
WO2024101440A1 (ja) * 2022-11-11 2024-05-16 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物
JP2024534111A (ja) * 2021-08-26 2024-09-18 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 芳香環系を含有する生物アンタゴニスト、その製造方法及び応用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7524167B2 (ja) * 2018-10-04 2024-07-29 トラビア セラピューティクス， インコーポレイテッド Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
BR112021012226A2 (pt) 2018-12-21 2021-09-08 Travere Therapeutics, Inc. Composições de esparsentano amorfo
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
US20230270718A1 (en) * 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
WO2022246200A1 (en) 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
WO2023127853A1 (ja) * 2021-12-28 2023-07-06 株式会社アークメディスン 化合物、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
EP4719402A1 (en) 2023-05-31 2026-04-08 Travere Therapeutics, Inc. Sparsentan for use in a method of treating iga-mediated diseases
KR20260089488A (ko) 2023-09-20 2026-06-15 트래비어 테라퓨틱스, 인코포레이티드 면역글로불린 A 신장병증(IgAN)의 치료를 위한 스파르센탄
CN118666826A (zh) * 2024-08-23 2024-09-20 成都臻拓医药科技有限公司 一种司帕生坦原料药的重结晶纯化方法
WO2026165438A1 (en) 2025-01-31 2026-08-06 Travere Therapeutics, Inc. Sparsentan for the treatment of patients post kidney transplantation with proteinuric iga nephropathy or fsgs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522058A (ja) * 2009-03-31 2012-09-20 リガンド・ファーマシューティカルズ・インコーポレイテッド 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アゴニストの経口製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26984A (id) * 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001044239A2 (en) 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) * 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
PL3536685T3 (pl) * 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
JP7524167B2 (ja) 2018-10-04 2024-07-29 トラビア セラピューティクス， インコーポレイテッド Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522058A (ja) * 2009-03-31 2012-09-20 リガンド・ファーマシューティカルズ・インコーポレイテッド 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アゴニストの経口製剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AM J PHYSIOL REGUL INTEGR COMP PHYSIOL, vol. 310, JPN6021029020, March 2016 (2016-03-01), pages 877 - 884, ISSN: 0004731476 *
CURR HYPERTENS REP, vol. 17, JPN6021029017, 2015, pages 57, ISSN: 0004731478 *
INT HEART J, vol. 56, no. 6, JPN6021029019, 2015, pages 585 - 586, ISSN: 0004731477 *
KIDNEY INTERNATIONAL, vol. 86, JPN6021029016, 2014, pages 896 - 904, ISSN: 0004731479 *
医学のあゆみ, vol. 243, no. 9, JPN6021029014, 2012, pages 758 - 762, ISSN: 0004731481 *
日腎会誌, vol. 53, no. 2, JPN6022010127, 2011, pages 78 - 123, ISSN: 0004731482 *
臨床病理, vol. 61, no. 7, JPN6021029015, 2013, pages 616 - 621, ISSN: 0004731480 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507739A (ja) * 2019-12-17 2023-02-27 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンによるｉｇａ腎症を治療する方法
JP7624995B2 (ja) 2019-12-17 2025-01-31 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンによるｉｇａ腎症を治療する方法
JP2025060686A (ja) * 2019-12-17 2025-04-10 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンによるｉｇａ腎症を治療する方法
JP7821870B2 (ja) 2019-12-17 2026-02-27 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンによるｉｇａ腎症を治療する方法
JP2024534111A (ja) * 2021-08-26 2024-09-18 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 芳香環系を含有する生物アンタゴニスト、その製造方法及び応用
WO2024101440A1 (ja) * 2022-11-11 2024-05-16 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Also Published As

Publication number Publication date
CN114788823A (zh) 2022-07-26
JP2025060754A (ja) 2025-04-10
ES3067967T3 (en) 2026-05-26
KR20220132030A (ko) 2022-09-29
CA3039819A1 (en) 2018-04-19
CN117085013A (zh) 2023-11-21
KR20230066644A (ko) 2023-05-16
WO2018071784A1 (en) 2018-04-19
US20210196688A1 (en) 2021-07-01
AU2017341825B2 (en) 2023-06-01
KR20190077348A (ko) 2019-07-03
AU2017341825A1 (en) 2019-04-11
US20250325522A1 (en) 2025-10-23
US20250325523A1 (en) 2025-10-23
JP2022137245A (ja) 2022-09-21
CN110049764A (zh) 2019-07-23
US10864197B2 (en) 2020-12-15
KR20240162167A (ko) 2024-11-14
CN116983302A (zh) 2023-11-03
EP4744733A2 (en) 2026-05-20
EP3525784B1 (en) 2026-01-28
JP2022141802A (ja) 2022-09-29
EP3525784A1 (en) 2019-08-21
AU2023219839A1 (en) 2023-09-07
AU2023219839B2 (en) 2025-08-21
BR112019007576A2 (pt) 2019-07-02
CN117017985A (zh) 2023-11-10
KR102528435B1 (ko) 2023-05-03
AU2025271121A1 (en) 2025-12-18
EP4744733A3 (en) 2026-07-29
US20200281901A1 (en) 2020-09-10
MA46524A (fr) 2019-08-21
US20190262317A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
US20250325522A1 (en) Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
US20220048900A1 (en) Amorphous sparsentan compositions
US11207299B2 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
WO2022246200A1 (en) Methods of treating kidney diseases or disorders
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
WO2025064688A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
BR122025008185A2 (pt) Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201009

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220715

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220725

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220726

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220728